September 11, 2020

Satsuma Pharmaceuticals, Inc. Announces Topline Results from EMERGETM Phase 3 Trial of STS101 for the Acute Treatment of Migraine

August 07, 2020

Satsuma Pharmaceuticals Announces Enrollment of First Patient in the  ASCEND™ Phase III Open-label Trial of STS101 for  Acute Treatment of Migraine

June 01, 2020

Satsuma Pharmaceuticals,Inc. Announces Completion of Enrollment for Phase 3 EMERGE Trial of STS101 for Acute Treatment of Migraine

May 19, 2020

Satsuma Pharmaceuticals Announces Poster Presentations on the American Academy of Neurology 2020 Science Highlights Virtual Platform

May 12, 2020

Satsuma Pharmaceuticals, Inc. Reports STS101 Development Progress in its First Quarter 2020 Financial Results

February 03, 2020

Satsuma Pharmaceuticals, Inc. Announces Publication of STS101 Phase 1 Clinical Trial Results in Headache: The Journal of Head and Face Pain

September 17, 2019

Satsuma Pharmaceuticals, Inc. Listed on NASDAQ

August 23, 2019

Satsuma Pharmaceuticals, Inc. Announces First Patient Dosed in EMERGE™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine

April 25, 2019

Satsuma Pharmaceuticals, Inc. Raises $62 Million in Series B Preferred Stock Financing

February 21, 2019

Satsuma Pharmaceuticals, Inc. announces advance of lead product candidate, STS101, into Phase 3 Efficacy Trial for Acute Migraine in 2019

June 19, 2018

Event: SNBL will exhibit a booth showcasing our nasal delivery technology at WCP 2018 KYOTO

June 15, 2018

Event: SNBL to present in vitro/in vivo evaluations of proprietary Nose-to-Brain delivery technology at CRS Annual Meeting 2018

April 2, 2018

New Website

December 19, 2016

Satsuma Pharmaceuticals Inc., Completes Third-party Allocation of New Shares - $12M Financing Accelerates Development of Migraine Therapeutic -

June 8, 2015

Homepage Renewal

June 5, 2015

SNBL's TR Company at the BIO One-on-One Partnering at the BIO International Convention 2015 in Philadelphia, June 15-18th

December 24, 2014

Termination of License Agreement with Besins Healthcare for Nasal Progesterone

October 16, 2014

News Release: SNBL Nasal Delivery Technology in The 505(b)(2) Forum

August 13, 2014

Business Collaboration Letter of Intent Signed between SNBL and Sosei Group Corporation and Progress on Development of Novel Nasal Epinephrine Product

September 26, 2013

Licensing Agreement for Nasal Drug Delivery Technology Platform -Nasal Dihydroergotamine for Treatment of Migraine Headache-

September 19, 2013

[News Release] Novel Nasal Epinephrine Shows Comparable Absorption to EpiPen(R) in a Feasibility Study

May 15, 2013

SNBL's NDS division is featured in the May 2013 Edition of Drug Development & Delivery Magazine.

April 18, 2013

Besins Healthcare, Shin Nippon Biomedical Laboratories, Ltd Announce Delivery Technology Licensing Agreement for Intranasal Progesterone

December 26, 2012

μco™ System is featured in the December 2012 edition of ONdrugDelivery magazine.

November 13, 2012

Results of a Meeting with the US Food and Drug Administration (FDA) Concerning the Development of Intranasal Zolmitriptan for Migraine

October 10, 2012

μco™ System is featured in the September 2012 edition of ONdrugDelivery magazine.

June 7, 2012

SNBL's Fit-lizer™ device is featured in the June 2012 Edition of Drug Development & Delivery Magazine.

May 5, 2012

μco™ System is featured in the April 2012 edition of ONdrugDelivery magazine.

April 4, 2012

Results of First Phase I Clinical Study for Intranasal Zolmitriptan Formulation (Migraine Drug)

February 10, 2011

Conclusion of Licensing Agreement with Pastorus

August 19, 2010

Results of a Meeting with the US Food and Drug Administration (FDA) Concerning the Development of Intranasal Granisetron; Planning for a Phase 3 Study to Improve Patient Quality of Life (QOL)

August 11, 2010

Intranasal Zolmitriptan: Clinical Study of Rapid Acting Migraine Drug - Preparations Underway for US Phase 1 Clinical Study -

May 12, 2010

Research Progress on TR-Flu, an Intranasal Flu Vaccine in Dry Powder Form (First Report)

2025｜2024｜2023｜2022｜2021｜2020〜